Her2-BATS and Pembrolizumab in Metastatic Breast Cancer

NCT03272334 | Active Not Recruiting Phase 1 Results DMC FDA Drug

• 1 other identifier: 19406
• Study Type: interventional
• Target: 22
• Locations: 1 country
• Sites: 1

Brief Summary

This proposal uses HER2Bi armed activated T-cells (HER2 BATs) to target breast cancer in combination with pembrolizumab (PBZ) in women with metastatic breast cancer (MBC). Phase I will determine a safe dose of the combination of PBZ and HER2 BATs in 3 to 18 patients. In the phase II portion, an additional 12 patients will be treated at the selected dose to further evaluate the safety and preliminary efficacy. Study treatment includes a combination of 8 infusions of BATs using a previously established schedule and one to three infusions of PBZ (200 mg per dose). PBZ will be added to 8 infusions of BATs in 3 schedules: #1) after the 8th BATs infusion; #2) after the 4th and 8th BATs infusions; and then, #3) before the 1st and after the 4th and 8th BATs infusions.

Conditions

Metastatic Breast Cancer

Keywords

Metastatic Breast Cancer; Adoptive Cell Therapy; Armed Activated T-cells; Bispecific Antibodies; Immunotherapy

Outcome Measures

Primary Outcomes (1)

• Dose Limiting Toxicities (Escalation and Expansion Cohorts)

  Maximum tolerated dose will be based on number of dose limiting toxicities in each schedule/arm

  From start of study treatment until 3 weeks after last dose of study treatment, assessed over about 10 weeks.

Secondary Outcomes (7)

• Dose Limiting Toxicities on the Selected Arm in the Expansion Cohort

  From start of study treatment until 3 weeks after last dose of study treatment, assessed over about 10 weeks.

• Objective Response Rate

  Imaging will be done prior to study treatment, 1 month, 3 months and 6 months after completion of study treatment (about 8.5 months after starting study treatment). Imaging will then be performed according to standard of care.

• Overall Survival

  Every 3 months following last study visit until death

• Progression-Free Survival

  Checked from enrollment through first progression, about every 3 months, through death or end of study

• Immune Response to Treatment in Blood

  Blood will be collected about 5 weeks before any treatment, just before first HER2 BATs infusion, before HER2 BATs #5, before HER2 BATs #8, and 2 weeks, 1 month, 3 months, and 6 months after last Pembrolizumab

Study Arms (3)

Schedule #1

EXPERIMENTAL

At approximately 4 weeks following leukapheresis, 8 infusions of HER2 BATs are given twice weekly in weeks #1, #2, #5, and #6 plus 1 infusion of Pembrolizumab in week #7. No interventions within weeks #3 and 4.

Drug: HER2 BATs with Pembrolizumab

Schedule #2

EXPERIMENTAL

At approximately 4 weeks following leukapheresis, 8 infusions of HER2 BATs are given twice weekly in weeks #1, #2, #5, and #6 plus 2 infusions of Pembrolizumab; the first given within weeks #3 - 4 and the second in week #7.

Drug: HER2 BATs with Pembrolizumab

Schedule #3

EXPERIMENTAL

At approximately 4 weeks following leukapheresis, 8 infusions of HER2 BATs are given twice weekly in weeks #1, #2, #5, and #6 plus 3 infusions of pembrolizumab; the first given one week prior to first BATs infusion, the second is given within weeks #3 - 4, and the third at week #7.

Drug: HER2 BATs with Pembrolizumab

Interventions

HER2 BATs with Pembrolizumab DRUG

8 infusions of HER2 BATs with 1-3 infusions of Pembrolizumab

Schedule #1; Schedule #2; Schedule #3

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Histologically confirmed breast cancer (infiltrating ductal or lobular breast carcinoma) with evidence of measurable metastatic disease. Metastatic disease must be biopsy proven.
• a. Since histologic type, lymphatic permeation, blood vessel invasion, and degree of anaplasia may be prognostic variables, appropriate slides of the primary lesion will be requested for future review. HER2, estrogen, and progesterone receptor positivity will be recorded.
• Measurable lesion. Patients are required to have at least one measurable non-bone lesion ≥10 mm that has not been irradiated.
• a. Measurable metastatic disease documented by radiograph, CT scan, PET/CT, MRI, or physical exam is required. Each subject will be required to have at least one measurable lesion that has not been irradiated with a minimum size in at least one diameter of ≥ 10 mm for liver lesions, lung, skin, and ≥ 15 mm lymph node metastases. Biopsy of recurrent site(s) is not required.
• Patients must have HER2 status determined by FISH or IHC. HER2 status of positive or negative are both eligible for the study.
• In order to be eligible for participation in this trial, the patient must also:
• Be female ≥ 18 years of age
• Be willing and able to provide written informed consent for the trial.
• Have a performance status (PS) ECOG 0-1
• Have a life expectancy ≥ 3 months
• Be eligible for apheresis, as determined by the Stem Cell Transplant team
• Demonstrate adequate organ function as defined below, all screening labs should be performed within 10 days prior to apheresis.
• Absolute lymphocyte count ≥ 500/mm3 Absolute neutrophil count (ANC) ≥1,500 /mcL Platelets ≥ 100,000 / mcL Hemoglobin ≥ 9 g/dL (or ≥5.6 mmol/L without transfusion or EPO dependency (within 7 days of assessment) BUN ≤ 1.5 X upper limit of normal (ULN) Serum creatinine OR ≤1.5 X upper limit of normal (ULN) OR Measured or calculated creatinine clearance (GFR can also be used in place of creatinine or CrCl) ≥60 mL/min for subject with creatinine levels \> 1.5 X institutional ULN Serum total bilirubin ≤ 1.5 X ULN OR AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN OR ≤ 5 X ULN for subjects with liver metastases Albumin \>2.5 mg/dL International Normalized Ratio (INR) or Prothrombin Time (PT) ≤1.5 X ULN unless subject is receiving anticoagulant therapy Activated Partial Thromboplastin Time (aPTT) as long as PT or PTT is within therapeutic range of intended use of anticoagulants
• Female patients of childbearing potential should have a negative urine or serum pregnancy test at screening. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
• Female patients of childbearing potential must be willing to use an adequate method of contraception as outlined in Section 4.5.2, for the course of the study through 120 days after the last dose of study medication.

You may not qualify if:

• The patient must be excluded from participating in the trial if the subject:
• Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to leukapheresis.
• Has a known history of active TB (Bacillus Tuberculosis)
• Hypersensitivity to PBZ or any of its excipients.
• Lack of recovery (i.e., ≤ Grade 1 or baseline prior to last line of cancer therapy) from non-laboratory adverse events except ≤ Grade 2 neuropathy
• Has history of another malignancy within the past 5 years. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
• Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to leukapheresis. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.
• Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
• Has known history of, or any evidence of active, non-infectious pneumonitis.
• Has an active infection requiring systemic therapy.
• Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
• Is pregnant or breastfeeding, or expecting to conceive children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.
• Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
• Has Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies) or known history of Hepatitis B (e.g., HBsAg reactive) or Hepatitis C antibody is detected. Note: Patients may be eligible if HCV antibody is detected as long as HCV viral load is undetectable following an FDA approved treatment regimen
• Has received a live vaccine within 30 days of apheresis. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.

Sponsors & Collaborators

• University of Virginia: lead
• Merck Sharp & Dohme LLC: collaborator

Study Sites (1)

Ashley Donihee

Charlottesville, Virginia, 22908, United States

Location

Related Publications (2)

• Lum LG, Thakur A, Al-Kadhimi Z, Colvin GA, Cummings FJ, Legare RD, Dizon DS, Kouttab N, Maizel A, Colaiace W, Liu Q, Rathore R. Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial. Clin Cancer Res. 2015 May 15;21(10):2305-14. doi: 10.1158/1078-0432.CCR-14-2280. Epub 2015 Feb 16.

  PMID: 25688159 BACKGROUND

• Vaishampayan U, Thakur A, Rathore R, Kouttab N, Lum LG. Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients. Prostate Cancer. 2015;2015:285193. doi: 10.1155/2015/285193. Epub 2015 Feb 23.

  PMID: 25802762 BACKGROUND

MeSH Terms

Conditions

Breast Neoplasms

Interventions

pembrolizumab

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Results Point of Contact

• Title: Patrick Dillon, MD
• Organization: University of Virginia

pmd5b@uvahealth.org

434 924 8073

Study Officials

• Patrick Dillon, MD

  University of Virginia

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor, Hematology and Oncology

Model Details: Pembrolizumab administered in combination with HER2 Bispecific Antibody Armed Activated T-Cell (BATs) infusions

Study Record Dates

• First Submitted: August 28, 2017
• First Posted: September 5, 2017
• Study Start: December 29, 2017
• Primary Completion: November 30, 2024
• Study Completion (Estimated): January 1, 2031
• Last Updated: February 27, 2026
• Results First Posted: February 27, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)